



СРПСКИ АРХИВ
ЗА ЦЕЛОКУПНО ЛЕКАРСТВО
SERBIAN ARCHIVES
OF MEDICINE

Address: 1 Kraljice Natalije Street, Belgrade 11000, Serbia

+381 11 4092 776, Fax: +381 11 3348 653

E-mail: office@srpskiarhiv.rs, Web address: www.srpskiarhiv.rs

Paper Accepted*

ISSN Online 2406-0895

Review Article / Прегледни рад

Maja Lačković^{1,2}, Maja Ivković^{1,2}, Sreten Vićentić^{1,2}, Stefan Jerotić^{1,2}, Milica Nestorović^{1,2},
Tihomir Stojković³, Aleksandra M. Pavlović^{4,*}

The role of the blood-brain barrier in psychiatric disorders

Улога крвно-мождане баријере у психијатријским обољењима

¹University Clinical Center of Serbia, Clinic of Psychiatry, Belgrade, Serbia;

²University of Belgrade, Faculty of Medicine, Belgrade, Serbia;

³University of Belgrade, Faculty of Medicine, Institute of Clinical and Medical Biochemistry, Belgrade, Serbia;

⁴University of Belgrade, Faculty of Special Education and Rehabilitation, Belgrade, Serbia

Received: April 17, 2022

Revised: July 18, 2022

Accepted: August 1, 2022

Online First: August 25, 2022

DOI: <https://doi.org/10.2298/SARH220417081L>

***Accepted papers** are articles in press that have gone through due peer review process and have been accepted for publication by the Editorial Board of the *Serbian Archives of Medicine*. They have not yet been copy-edited and/or formatted in the publication house style, and the text may be changed before the final publication.

Although accepted papers do not yet have all the accompanying bibliographic details available, they can already be cited using the year of online publication and the DOI, as follows: the author's last name and initial of the first name, article title, journal title, online first publication month and year, and the DOI; e.g.: Petrović P, Jovanović J. The title of the article. *Srp Arh Celok Lek*. Online First, February 2017.

When the final article is assigned to volumes/issues of the journal, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the journal.

The date the article was made available online first will be carried over.

***Correspondence to:**

Aleksandra M. PAVLOVIĆ

University of Belgrade, Faculty of Special Education and Rehabilitation

Visokog Stevana 2, Belgrade, Serbia

E-mail: aleksandra3003@yahoo.com

The role of the blood-brain barrier in psychiatric disorders

Улога крвно-моздане баријере у психијатријским обољењима

SUMMARY

The blood-brain barrier (BBB) is formed by continuous, closely connected endothelial cells, enveloped in the basal lamina, pericytes, and foot extensions of astrocytes. BBB has a vital role in brain metabolism and protects the brain parenchyma from harmful agents present in the systemic circulation. Damage to the BBB and an increase in its permeability have an important role in many neurodegenerative diseases.

This paper aims to review the literature on the impact of the BBB damage on psychiatric illness, a largely neglected and under researched area. Links between BBB impairment and specific neuropsychiatric disorders are described including schizophrenia, affective disorders, dementias with behavioral disorders, and alcohol use disorder, with comparison to typical hereditary small vessel diseases affecting the BBB such as cerebral autosomal dominant arteriopathy with subcortical infarction and leukoencephalopathy (CADASIL) and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). The authors critically summarize possible pathogenic mechanisms linking BBB damage and these common disorders.

Keywords: blood-brain barrier; schizophrenia; affective disorders; alcohol use disorder; dementia; hereditary small vessel disease

САЖЕТАК

Крвно-моздана баријера (КМБ) се састоји од континураних, тесно спојених ендотелних ћелија омотаних базалном ламином, перичитима и стопаластим продужецима астроцита. КМБ има виталну функцију и мозданом метаболизму и штити моздани паренхим од штетних фактора присутних у системској циркулацији. Показано је да оштећење КМБ и повећање њене пропустљивости има значајну улогу у многим неуродегенеративним обољењима.

Циљ овога рада је преглед литературе о значају оштећења КМБ код психијатријских обољења, до сада занемареној и недовољно истраженој области. Повезаност између поремећаја КМБ и неуропсихијатријских поремећаја је посебно анализирана за схизофренију, афективне поремећаје, деменције са бихевиоралним изменама, поремећај употребе алкохола, са посебним освртом на наследне болести малих крвних судова мозга са оштећењем КМБ као што су церебрална аутозомално доминантна артериопатија са супкортикалним инфарктима и леукоенцефалопатијом (CADASIL) и митохондријска енцефаломиопатија са лактатном ацидозом и епизодама налик мозданом удару (MELAS). Аутори критички сумирају могуће патогенетске механизме који повезују оштећења КМБ са овим честим обољењима.

Кључне речи: крвно-моздана баријера; схизофренија; афективни поремећаји; поремећај употребе алкохола; деменција; наследне болести малих крвних судова мозга

INTRODUCTION

Current research has shown that various neurological diseases occur due to the structural and/or functional disorder of the blood-brain barrier (BBB) [1]. Most frequently studied entities include multiple sclerosis, infectious or inflammatory brain diseases, certain vascular as well as degenerative disease such as Alzheimer's (AD), Parkinson's disease, and amyotrophic lateral sclerosis [2]. The pathogenesis of these conditions includes damage to the occludent endothelial junction and subsequently increased BBB permeability, expression of a

procoagulant endothelial phenotype, as well as the production of free radicals and other mediators of inflammation [3]. Changes in the structure of the BBB can be transient and mild corresponding to the opening of the tight junctions, but also chronic with permanent damage to the BBB leading to alterations in protein and enzyme transport. The consequent activation of microglia and infiltration of the brain parenchyma with plasma proteins and immune cells induce the disruption of the central nervous system (CNS) homeostasis and damage to the surrounding brain tissue [1].

Interestingly, data in the literature on the impact of the BBB damage on psychiatric illnesses are mostly lacking. One intriguing contemporary hypothesis states that the BBB dysfunction and subsequent increase in its permeability may be the basis for the development of certain psychiatric disorders [4]. Previous research on experimental models indicated that the development of psychiatric conditions as well as the co-existence or overlap between certain neurological and psychiatric diseases may be explained by BBB disruption, which may widen the therapeutic approach [4]. Therefore, our paper aims to review possible pathogenetic mechanisms linking BBB disruption to the main psychiatric conditions.

THE STRUCTURE OF THE BBB

The BBB is a very complex cellular system consisting of endothelial cells, pericytes, perivascular microglia, astrocytes, and continuous basal laminae made of pericytes and foot extensions of astrocytes [2]. These components configure a very restrictive wall named BBB as its main role is to maintain a safe extracellular environment for CNS neurons [2]. The impermeability of the BBB is mostly achieved through the specific structure of the endothelium [3]. The BBB protects the brain from toxins in the blood and controls the transport of glucose (glucose transporter, Glut 1) and other nutrients to the CNS, but also manages the removal of various metabolites from the brain tissue.

The vascular wall lining the brain capillaries is characteristically formed by uninterrupted endothelial cells surrounded by branching cytoplasmatic extension of astrocytes and pericytes [3]. The **endothelium** of the BBB is continuous, and endothelial cells form an inner sheath of capillaries. These cells secrete numerous vasoactive substances that have a role in the regulation of the vascular tone [1]. Nitric monoxide (NO) is one of the most important vasodilators secreted by these cells, and its deficiency is an important indicator of endothelial dysfunction [5]. Endothelial cells are interconnected, predominantly by occluding (tight) junctions, the most important components of BBB, as well as with adherent compounds that provide mechanical stability [3]. Occluding compounds form a selective barrier that regulates and restricts the transport of certain metabolites, ions, macromolecules, toxic substances, pathogenic microorganisms, erythrocytes, and leukocytes from blood to the brain tissue [3]. Various nutrients including glucose and amino acids enter the brain tissue through the transporters, while the introduction of large molecules such as insulin, leptin, transferrin, and low-density lipoprotein (LDL) is carried out by receptor endocytosis [2]. Recent research has shown that claudins (CLDNs), a family of 24 members, are the main structural and functional elements of the occluding compounds [4]. Specifically, claudin-5 (CLDN5) is the most expressed occluding compound in the BBB, and its suppression leads to BBB damage and the emergence of a schizophrenia-like phenotype in experimental animals (mice) [4, 6]. In addition, important integral proteins of occluding compounds are CLDN-12 [2]. The transmembrane claudin and occluding proteins are linked by the Zonula Occludens-1 (ZO-1) protein to the actin filaments of the endothelial cell cytoskeleton, making ZO-1 essential for maintaining the integrity and functioning of the occluding compound [2]. The function of the occluding compound is regulated by a number of factors, including vascular endothelial growth factor (VEGF), G-proteins, tyrosine kinases, Ca⁺⁺, cAMP, proteases, TNF- α (tumor necrosis factor- α) [7].

The characteristic feature of **pericytes** are contractile, branched cytoplasmatic extensions surrounding endothelial cells. They express receptors for vasoactive mediators, such as catecholamines, endothelin-1 (ET-1), and angiotensin II (AngII) [1]. All these molecules play a vital role in regulating cerebral blood flow through capillaries [1]. The pericytes are critical in the maintenance, stability, and selectivity of the BBB. The most important factor for the functioning and homeostasis of pericytes and BBB itself, is the platelet-derived growth factor (PDGF) [3]. The role of pericytes have been evidenced in the cerebral autosomal dominant arteriopathy with subcortical infarction and leukoencephalopathy (CADASIL), AD, Huntington's disease (HD) and amyotrophic lateral sclerosis [3].

The foot extensions of **astrocytes** are interconnected by junctions that communicate with each other (Gap Junctions; nexus) and form a perivascular glial membrane that envelops the outer surface of the brain capillaries [2]. Astrocytes regulate endothelial vasodynamic, proliferative and phenotypic activities as well as their capacity for the formation of occluding compounds within the BBB [1]. Astrocytes synthesize factors such as glial neurotrophic factor (GDNF), TGF- β -growth bFGF (basal fibroblast growth factor), and angiopoietin-1, all acting as stimulants for the endothelial cells [8]. They also contain aquaporins (AQPs), and water transport channels, with AQP4 being specific for astrocyte foot extensions [9]. Changes in the BBB stability, as well as changes in the secretion of antioxidative compounds of glutathione (GSH) and superoxide dismutase (SOD), are implied in the pathogenesis of many neurodegenerative diseases [2].

Perivascular microglia is positioned between the endothelial basal lamina and cytoplasmatic extensions of astrocytes, making an interconnected web of brain macrophages [10]. These macrophages have significant phagocytic activity, by which they internalize proteins and other substances, thus reducing the detritus from the brain parenchyma. Moreover, these cells can secrete specific cytokines enhancing the inflammatory response [11].

Perivascular microglia have a significant role in the presentation of antigens in the CNS. This has been demonstrated in experimental allergic encephalomyelitis and studied in animal models of multiple sclerosis [12]. Microglial cells can quickly reduce inflammation and eliminate infectious agents before they damage brain tissue [11].

In recent years several studies identified BBB dysfunction and its increased permeability as potentially important factor in the development of psychiatric disorders [4, 13, 14]. Numerous control mechanisms can become disrupted due to infiltration of brain parenchyma with neurotoxic substances, resulting in inflammation and oxidative stress. Our previous work has shown that oxidative stress has a significant role in the development and progression of psychiatric disorders, including major depressive disorder (MDD) and bipolar affective disorder (BAD) [15, 16]. In addition to affective disorders, current literature recognizes the role of BBB dysfunction in schizophrenia, dementia, and addictive disorders such as alcohol abuse.

BBB AND SCHIZOPHRENIA

Schizophrenia is a heterogeneous clinical syndrome characterized by a constellation of symptoms divided into positive, negative, and cognitive, often severely impacting individual functionality [17]. The pathogenesis of schizophrenia is still poorly understood, and the variability of its clinical manifestations indicates several distinct pathophysiological processes in play [17]. The roles of neurotransmission disturbances, immune response, and low-grade inflammation (“low-grade encephalitis”) have been all implied [18, 19]. Recent data indicate that the oxidative stress associated with neuroinflammation and neurovascular endotheliopathy can lead to impairment of BBB integrity and decreased cerebral perfusion and disruption of neuronal homeostasis in patients with schizophrenia [13, 19]. The damage to occluding compounds between endothelial cells of continuous BBB capillaries (i.e., decreased CLDN5

expression in the hippocampus) has been demonstrated in schizophrenia [20]. Decreased levels of mRNA in charge of the synthesis of occluding compounds such as CLDN5, CLDN12, and ZO-1 appear to be associated with schizophrenia [20]. In addition, 5-HT regulates the functioning of the BBB by increasing the expression of CLDN5, potentially playing an important role in the pathogenesis of schizophrenia. [6].

The plasma levels of astrocyte protein S100B are elevated in schizophrenia, making S100B protein levels a putative treatment marker particularly in patients with predominantly negative symptoms [14, 20]. Since S100B is a calcium-binding protein, specifically found in the astrocytes, its elevation indicates astrocyte activation with increased permeability of the BBB, which may lead to neurodegeneration [21]. Moreover, S100B synthesis induces oxidative stress, potentially resulting in the promotion of NO synthesis and an increase of pro-inflammatory cytokines which has a detrimental effect on neuronal integrity [1, 20]. There are also data indicating beneficial effects of psychotropic medications by reducing the oxidative stress in the CNS [22].

BBB ROLE IN AFFECTIVE DISORDERS

There is an increasing body of evidence linking major affective disorders (MDD and BAD) to BBB dysfunction [23–26]. Both functional and structural abnormalities are heterogenous and widespread in schizophrenia [27]. Similarly to schizophrenia, elevated values of S100B have been observed in the serum of patients with affective disorders, and are also associated with the severity of symptoms in depression [28]. Moreover, the elevation of S100B is a predictor of a successful response to antidepressant therapy in MDD [29]. In addition, chronic social stress can have an effect on CLDN5 levels, potentially affecting the BBB integrity [26]. The most intense passage of proinflammatory cytokines through the

dysfunctional BBB has been observed in the region of nucleus accumbens, which is a brain region important for mood regulation [29].

Recent data indicate an association between mRNA levels for CLDN5, CLDN12, and ZO-1 and the onset and duration of MDD and BAD [4]. It has been shown that BAD patients with impaired BBB integrity have a more pronounced clinical expression of the disease and its progression [4, 30]. Both acute or chronic BBB damage increases the passage of proinflammatory cytokines such as IL-1, IL-6, TNF- α , and reactive oxygen species (ROS) [15]. This triggers the activation of microglial cells with a central role in the pathway of neuroinflammation, and also promotes local oligodendrocyte and myelin sheath damage, compromising neuronal network integrity [15, 31]. Positron emission tomography (PET) imaging revealed increased microglial activity and neuroinflammation in the hippocampus of patients with affective disorders [4]. In addition, oligodendrocyte density is decreased in BAD which indicates potential instability of the neural circuitry [31].

BBB STATUS IN DEMENTIA

Frequently, patients with dementia present with additional psychiatric symptoms such as depressed mood, agitation, anxiety, apathy, or psychosis [32, 33]. The brain endothelium becomes progressively dysfunctional in aging, with corresponding alterations in the BBB [34]. However, in the two most common types of dementia, AD and vascular dementia, the critical role of BBB dysfunction has been documented in the last years [2, 3]. The data is especially robust concerning pericyte degeneration [3]. It has been shown that an influx of immune cells (CD4+ and CD8 T cells, dendritic cells, B cells) via disturbed BBB, lead to damage of multiple efflux transporters (ATP dependent pumps that remove harmful agents out of the brain tissue), and accumulation of molecules prone to aggregation, such as amyloid beta [1, 35]. In AD in particular, amyloid beta as the main component of amyloid plaques is a key pathological feature

of the disease [35]. High levels of amyloid beta and oligopeptides lead to activation of microglial cells and astrocytes, resulting in increased production of toxic molecules, and consequent synaptic and neuronal damage [1]. Microglia activated in relation to amyloid beta plaques leads to the activation of astrocytes which results in the release of cytokines such as IL-1, TNF- β , TNF- α , TGF- β , NGF, bNGF, and reactive oxygen species [1]. In addition, the amyloid beta has been shown to stimulate the nuclear kappaB transcription factor (NF- κ B) which in turn also induces the transcription of TNF- α , IL-1, IL-6, MCP-1 (monocyte chemotaxis-1 protein), and NO synthase [34]. Activation and migration of immune cells, as well as the release of cytokines, damage the integrity of the BBB [1]. The dysfunction of BBB is reflected in the impaired functioning of the amyloid beta transporter whose role is to transport these peptides from brain tissue to the blood, via BBB [1, 36]. Dysfunction of the amyloid beta transporter could be the precipitant in the cascade of events leading to the damage of neurons, synapses, and glial cells [36].

The pathophysiology of the subcortical small-vessel disease, the most frequent type of vascular cognitive impairment, is also characterized by endothelial damage and BBB dysfunction [32, 33, 37, 38]. Cerebral hypoxia due to vascular damage leads to increased levels of inflammatory molecules causing apoptosis [34]. The inflammatory molecules such as IL-1, IL-6, MMPs (MMP-2, MMP-9), TNF α , and TLR4 (toll-like receptor 4) cause demyelination and damage to the axons and oligodendrocytes associated with the white matter lesions [33, 37]. Besides risk factors, the clinical presentation including cognitive decline and behavioral changes, AD and vascular dementia also share several aspects of brain pathology, such as increased oxidative stress, disturbed amyloid beta clearance, and BBB disruption [33, 36].

BBB IN ALCOHOL USE DISORDER

Cognitive decline is common in patients with alcohol use disorder [38]. Largely, an association between alcohol use and the risk for dementia has been demonstrated in studies with robust methodology [39]. Particularly vulnerable might be the elderly and patients with documented neuroinflammatory conditions. Although the pathophysiological pathways of neurodegeneration associated with alcohol use are not sufficiently explored, it is clear that dietary deficiencies, such as depletion of vitamin B1 and B12, in combination with alcohol metabolites (such as acetaldehyde) have a neurotoxic effect [40, 41, 42]. In addition, chronic alcohol abuse leads to increased BBB permeability via the inhibition of protein expression such as ZO-1, occludins, VE-cadherins, AQP4), thus stimulating neuroinflammation and oxidative stress, most intensely in the hippocampal region [41]. In vitro studies demonstrated a detrimental effect of alcohol on tight junctions, endoplasmic reticulum, and an increase in reactive oxygen species production [41, 42].

BBB STATUS IN HEREDITARY CEREBRAL SMALL VESSEL DISEASE

The BBB likely has an important role in the pathogenesis of the CADASIL, the most frequent inherited form of vascular dementia [43]. This clinical phenotype is characterized by four basic manifestations: strokes, migraine with aura, psychiatric symptoms, and cognitive decline that progresses to subcortical vascular dementia [44]. Symptomatology of CADASIL can start with neuropsychiatric symptoms, sometimes delaying the diagnosis, with depression being the most frequent psychiatric manifestation [44, 45]. The main pathological characteristics of CADASIL are damage to smooth muscle cells of small cerebral arteries and arterioles, as well as deposition of granular osmiophilic material (GOM) in the vascular wall, due to mutation in the Notch3 gene on chromosome 19p13 [46, 47]. Recent data suggest a

significant role for BBB in this syndrome, with pronounced destruction of pericytes in the vascular wall of the brain, increasing the permeability of the BBB [48].

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is a rare hereditary progressive systemic disease with encephalopathy as a leading clinical feature [45, 49]. Although the most prominent clinical manifestations of the MELAS are neurological, comprising migraine, stroke-like episodes, seizures, and cognitive decline, depressed mood, anxiety, and behavioral changes are often neglected but important clinical features [44, 45, 49]. At the core of this syndrome are 29 specific point mutations documented so far, occurring at the level of various mitochondrial DNA (mtDNA) [45]. The key pathological process is a disorder in the synthesis of intramitochondrial proteins including respiratory chain enzymes and leading to reduced ATP synthesis [49]. Endothelial dysfunction is also evidenced in the pathogenesis of stroke-like episodes since there is a lack of vasodilatation in these patients due to reduction of NO synthesis by the endothelium [49]. There is also the metabolic hypothesis based on a generalized mitochondrial cytopathy, but the neuro-vascular hypothesis merging all potential pathological pathways appears most comprehensive [49].

CONCLUSION

There is evidence of involvement of all elements of the BBB in major psychiatric disorders as well as neurological conditions with behavioral changes. The role of astrocytes seems important since damage to the BBB leads to astrocyte activation and altered gene expression, resulting in disturbances in the extracellular environment of neurons. Activation of astrocytes also increases cytokine synthesis and secretion, thus contributing to local inflammation of brain tissue. Therefore, the “astrocytic hypothesis” of schizophrenia and depression, as well as the “low-grade encephalitis” hypothesis of schizophrenia remain highly

relevant today. Importantly, emerging infectious agents, such as SARS-CoV-2 virus infection, might add additional knowledge to the inflammatory processes adding to psychiatric conditions and cognitive disturbances. As taking into account the BBB hypothesis for the development of certain psychiatric disorders seems justified, we advocate for the development of precise molecular markers which would enable clinicians to measure the presence and the degree of BBB damage, as well as markers of brain parenchyma inflammation connected to BBB dysfunction in these entities. Increasing knowledge of these pathogenetic mechanisms may open new frontiers in the therapeutic approach to these chronic and burdening conditions.

Conflict of interest: None declared.

REFERENCES

1. Kadry H, Noorani B, Cucullo L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. *Fluids Barriers CNS*. 2020 Nov 18; 17(1): 69. PubMed PMID: 33208141; PubMed Central PMCID: PMC7672931.
2. Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. *Nat Rev Neurol*. 2018 Mar; 14(3): 133-150. PubMed PMID: 29377008; PubMed Central PMCID: PMC5829048.
3. Lendahl U, Nilsson P, Betsholtz C. Emerging links between cerebrovascular and neurodegenerative diseases—a special role for pericytes. *EMBO Rep*. 2019 Nov 5; 20(11): e48070. PubMed PMID: 31617312; PubMed Central PMCID: PMC6831996.3.
4. Greene C, Hanley N, Campbell M. Blood-brain barrier associated tight junction disruption is a hallmark feature of major psychiatric disorders. *Transl Psychiatry*. 2020 Nov 2; 10(1): 373. PubMed PMID: 33139732; PubMed Central PMCID: PMC7606459.
5. Ashby JW, Mack JJ. Endothelial Control of Cerebral Blood Flow. *Am J Pathol*. 2021 Nov; 191(11):1906-1916. doi: 10.1016/j.ajpath.2021.02.023. Epub 2021 Mar 10. PMID: 33713686.
6. Sugimoto K, Ichikawa-Tomikawa N, Nishiura K, Kunii Y, Sano Y, Shimizu F, Kakita A, et al. Serotonin/5-HT1A Signaling in the Neurovascular Unit Regulates Endothelial CLDN5 Expression. *Int J Mol Sci*. 2020 Dec 29; 22(1): 254. PubMed PMID: 33383868; PubMed Central PMCID: PMC7795278.
7. Sanchez-Cano F, Hernández-Kelly LC, Ortega A. The Blood-Brain Barrier: Much More Than a Selective Access to the Brain. *Neurotox Res*. 2021 Dec; 39(6):2154-2174. doi: 10.1007/s12640-021-00431-0. Epub 2021 Oct 22. PMID: 34677787.
8. Lee SW, Kim WJ, Choi YK, Song HS, Son MJ, Gelman IH, et al. SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. *Nat Med*. 2003 Jul; 9(7): 900-6. PubMed PMID: 12808449.
9. Archie SR, Al Shoyaib A, Cucullo L. Blood-Brain Barrier Dysfunction in CNS Disorders and Putative Therapeutic Targets: An Overview. *Pharmaceutics*. 2021 Oct 26; 13(11):1779. doi: 10.3390/pharmaceutics13111779.
10. Yang T, Guo R, Zhang F. Brain perivascular macrophages: Recent advances and implications in health and diseases. *CNS Neurosci Ther*. 2019 Dec; 25(12):1318-1328. PubMed PMID: 31749316; PubMed Central PMCID: PMC7154594
11. Jurga AM, Paleczna M, Kuter KZ. Overview of General and Discriminating Markers of Differential Microglia Phenotypes. *Front Cell Neurosci*. 2020 Aug 6; 14:198. PubMed PMID: 32848611; PubMed Central PMCID: PMC7424058.
12. Császár E, Lénárt N, Cserép C, Környei Z, Fekete R, Pósfai B, et al. Microglia modulate blood flow, neurovascular coupling, and hypoperfusion via purinergic actions. *J Exp Med*. 2022 Mar 7; 219(3):e20211071. doi: 10.1084/jem.20211071. Epub 2022 Feb 24. PMID: 35201268.
13. Puvogel S, Palma V, Sommer IEC. Brain vasculature disturbance in schizophrenia. *Curr Opin Psychiatry*. 2022 Mar 9. doi: 10.1097/YCO.0000000000000789. Online ahead of print. PMID: 35266904.
14. Pollak TA, Drndarski S, Stone JM, David AS, McGuire P, Abbott NJ. The blood-brain barrier in psychosis. *Lancet Psychiatry*. 2018 Jan; 5(1):79-92. PubMed PMID: 28781208.
15. Lačković M, Rovčanin B, Pantović M, Ivković M, Petronijević N, Damjanović A. Association of oxidative stress with the pathophysiology of depression and bipolar disorder. *Arch Biol Sci* 2013; 65(1): 369-373.
16. Lačković M. Analiza antioksidativnog statusa kod bolesnika sa unipolarnim i bipolarnim afektivnim poremećajem. Doktorska disertacija. Medicinski fakultet Univerziteta u Beogradu, 2016.
17. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. *Lancet*. 2016 Jul 2; 388(10039):86-97. PubMed PMID: 26777917; PubMed Central PMCID: PMC4940219.
18. Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O. Neuroinflammation and psychiatric illness. *J Neuroinflammation*. 2013 Apr 1; 10:43. PubMed PMID: 23547920; PubMed Central PMCID: PMC3626880.
19. Varanoske AN, McClung HL, Sepowitz JJ, Halagarda CJ, Farina EK, Berryman CE, et al. Stress and the gut-brain axis: Cognitive performance, mood state, and biomarkers of blood-brain barrier and intestinal permeability following severe physical and psychological stress. *Brain Behav Immun*. 2022 Mar; 101:383-393. doi: 10.1016/j.bbi.2022.02.002. Epub 2022 Feb 5. PMID: 35131441.
20. Kozłowska E, Brzezińska-Błaszczak E, Agier J, Wysokiński A, Żelechowska P. Alarmins (IL-33, sST2, HMGB1, and S100B) as potential biomarkers for schizophrenia. *J Psychiatr Res*. 2021 Jun; 138:380-387. doi: 10.1016/j.jpsychires.2021.04.019. Epub 2021 Apr 29.
21. Dunn C, Sturdivant N, Venier S, Ali S, Wolchok J, Balachandran K. Blood-Brain Barrier Breakdown and Astrocyte Reactivity Evident in the Absence of Behavioral Changes after Repeated Traumatic Brain Injury. *Neurotrauma Rep*. 2021 Aug 27; 2(1):399-410. PubMed PMID: 34901939; PubMed Central PMCID: PMC8655814.

22. Stojković T, Radonjić NV, Velimirović M, Jevtić G, Popović V, Doknić M, Petronijević ND. Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain. *Prog Neuropsychopharmacol Biol Psychiatry*. 2012 Oct 1;39(1):192-9. doi: 10.1016/j.pnpbp.2012.06.013.
23. Loosen PT, Shelton RC. Mood disorders. In: *Current diagnosis and treatment: Psychiatry* (Ebert MH, Leckman JF, Petrakis IL, eds). Third edition. New York: McGraw-Hill Education, 2019.
24. Nestorović M. Samoubistva psihijatrijskih bolesnika – sudskomedicinski aspekti. Diplomski rad. Medicinski fakultet Univerziteta u Beogradu, Katedra Sudska medicina. Beograd, 2020.
25. Dudek KA, Dion-Albert L, Lebel M, LeClair K, Labrecque S, Tuck E, et al. Molecular adaptations of the blood-brain barrier promote stress resilience vs. depression. *Proc Natl Acad Sci U S A*. 2020 Feb 11; 117(6): 3326-3336. PubMed PMID: 31974313; PubMed Central PMCID: PMC7022213.
26. Ivković M, Pantović-Stefanović M, Petronijević N, Dunjić-Kostić B, Velimirović M, Nikolić T, et al. Predictive value of sICAM-1 and sVCAM-1 as biomarkers of affective temperaments in healthy young adults. *J Affect Disord*. 2017 Jan 1;207:47-52. doi: 10.1016/j.jad.2016.09.017.
27. Komatsu H, Onoguchi G, Jerotic S, Kanahara N, Kakuto Y, Ono T, et al. Retinal layers and associated clinical factors in schizophrenia spectrum disorders: a systematic review and meta-analysis. *Mol Psychiatry*. 2022 May 2. doi: 10.1038/s41380-022-01591-x. Epub ahead of print. PMID: 35501407.
28. Schroeter ML, Sacher J, Steiner J, Schoenknecht P, Mueller K. Serum S100B represents a new biomarker for mood disorders. *Curr Drug Targets*. 2013 Oct;14(11): 1237-48. PubMed PMID: 23701298; PubMed Central PMCID: PMC3821390.
29. Menard C, Pfau ML, Hodes GE, Kana V, Wang VX, Bouchard S, et al. Social stress induces neurovascular pathology promoting depression. *Nat Neurosci*. 2017 Dec; 20(12): 1752-1760. PubMed PMID: 29184215; PubMed Central PMCID: PMC5726568.
30. Kamintsky L, Cairns KA, Veksler R, Bowen C, Beyea SD, Friedman A, et al. Blood-brain barrier imaging as a potential biomarker for bipolar disorder progression. *Neuroimage Clin*. 2020; 26:102049. PubMed PMID: 31718955; PubMed Central PMCID: PMC7229352.
31. Patel JP, Frey BN. Disruption in the Blood-Brain Barrier: The Missing Link between Brain and Body Inflammation in Bipolar Disorder? *Neural Plast*. 2015;2015:708306. PubMed PMID: 26075104; PubMed Central PMCID: PMC4444594.
32. Verdelho A, Wardlaw J, Pavlovic A, Pantoni L, Godefroy O, Duering M, et al. Cognitive impairment in patients with cerebrovascular disease: A white paper from the links between stroke ESO Dementia Committee. *Eur Stroke J*. 2021 Mar; 6(1):5-17. PubMed PMID: 33817330; PubMed Central PMCID: PMC7995319.
33. Pavlovic AM, Pekmezovic T, Zidverc Trajkovic J, Svabic Medjedovic T, Veselinovic N, Radojicic A, et al. Baseline characteristic of patients presenting with lacunar stroke and cerebral small vessel disease may predict future development of depression. *Int J Geriatr Psychiatry*. 2016 Jan;31(1):58-65. PubMed Central PMID: 25821003.
34. Hussain B, Fang C, Chang J. Blood-Brain Barrier Breakdown: An Emerging Biomarker of Cognitive Impairment in Normal Aging and Dementia. *Front Neurosci*. 2021 Aug 19;15:688090. PubMed PMID: 34489623; PubMed Central PMCID: PMC8418300.
35. He Y, Ruganzu JB, Jin H, Peng X, Ji S, Ma Y, et al. LRP1 knockdown aggravates A β 1-42-stimulated microglial and astrocytic neuroinflammatory responses by modulating TLR4/NF- κ B/MAPKs signaling pathways. *Exp Cell Res*. 2020 Sep 15;394(2):112166. PubMed PMID: 32645395.
36. Cai Z, Qiao PF, Wan CQ, Cai M, Zhou NK, Li Q. Role of Blood-Brain Barrier in Alzheimer's Disease. *J Alzheimers Dis*. 2018; 63(4): 1223-1234. PubMed PMID: 29782323.
37. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. *Lancet Neurol*. 2019 Jul;18(7):684-696. doi: 10.1016/S1474-4422(19)30079-1. Epub 2019 May 13.
38. Kettunen P, Bjerke M, Eckerström C, Jonsson M, Zetterberg H, Blennow K, et al. Blood-brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein- β in patients with subcortical small-vessel disease. *Alzheimers Dement (Amst)*. 2022 Mar 25;14(1):e12296. doi: 10.1002/dad2.12296. PMID: 35356486; PMCID: PMC8949877.
39. Peng B, Yang Q, B Joshi R, Liu Y, Akbar M, Song BJ, et al. Role of Alcohol Drinking in Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis. *Int J Mol Sci*. 2020 Mar 27; 21(7): 2316. PubMed PMID: 32230811; PubMed Central PMCID: PMC7177420.
40. Carrino D, Branca JJV, Becatti M, Paternostro F, Morucci G, Gulisano M, et al. Alcohol-Induced Blood-Brain Barrier Impairment: An In Vitro Study. *Int J Environ Res Public Health*. 2021 Mar 7;18(5):2683. PubMed PMID: 33799986; PubMed Central PMCID: PMC7967408.
41. Koch M, Fitzpatrick AL, Rapp SR, Nahin RL, Williamson JD, Lopez OL, et al. Alcohol Consumption and Risk of Dementia and Cognitive Decline Among Older Adults With or Without Mild Cognitive Impairment. *JAMA Netw Open*. 2019 Sep 4; 2(9): e1910319. PubMed PMID: 31560382; PubMed Central PMCID: PMC6777245.

42. Vićentić S, Dimitrijević I. Dualna dijagnoza - mentalni poremećaji vs. zloupotreba psihoaktivnih supstanci. *Engrami* 2015; 37 (3): 33-9.
43. Uchida Y, Kan H, Sakurai K, Arai N, Inui S, Kobayashi S, et al. Iron leakage owing to blood-brain barrier disruption in small vessel disease CADASIL. *Neurology*. 2020 Sep 1;95(9):e1188-e1198. PubMed Central PMID: 32586899.
44. Lačković M, Damjanović A, Ivković M, Pantović M, Bajcetić M, Rovčanin B, et al. Depression in Cadasil patients. *Arch. Biol. Sci., Belgrade* 2014; 66(3): 1187-1194.
45. Lačković M, Bajcetić M, Rovčanin B. Nasledne bolesti malih krvnih sudova mozga. U: Lačković V. i sar., *Histologija i embriologija kardiovaskularnog i limfnog vaskularnog sistema — klinički značaj* (Kanjuh V, Todorović V, urednici). Crnogorska akademija nauka i umjetnosti, Klinički centar Crne Gore, Podgorica 2020, str. 307-314. ISBN 978-86-7215-468-9.
46. Lackovic V, Bajcetic M, Lackovic M, Novakovic I, Labudović Borović M, Pavlovic A, et al. Skin and sural nerve biopsies: ultrastructural findings in the first genetically confirmed cases of CADASIL in Serbia. *Ultrastruct Pathol*. 2012 Oct; 36(5): 325-35. PubMed PMID: 23025651.
47. Di Donato I, Bianchi S, De Stefano N, Dichgans M, Dotti MT, Duering M, et al. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects. *BMC Med*. 2017 Feb 24; 15(1): 41. PubMed PMID: 28231783; PubMed Central PMCID: PMC5324276.
48. Ruchoux MM, Kalaria RN, Román GC. The pericyte: A critical cell in the pathogenesis of CADASIL. *Cereb Circ Cogn Behav*. 2021;2:100031. PubMed PMID: 34950895; PubMed Central PMCID: PMC8661128.
49. Cheng W, Zhang Y, He L. MRI Features of Stroke-Like Episodes in Mitochondrial Encephalomyopathy With Lactic Acidosis and Stroke-Like Episodes. *Front Neurol*. 2022 Feb 9;13:843386. PubMed PMID: 35222261; PubMed Central PMCID: PMC8863858.